Internal Medicine, Endocrinology, Diabetes, & Metabolism · Caguas, PR
NPI
1245565696
Since 2009
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
Ave Las Americas Bs4 Bairoa
Caguas, PR, 00725
Phone (787) 746-7066
Groups this clinician bills Medicare through
Medicare paid, 2024
$7,426
131 services
Medicare patients, 2024
51
Average age 74
Drug cost, 2024
$3.0M
22,298 prescriptions
Company payments, 2025
$658
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ivan E Laboy-Ortiz was code 99213 (office e&m - established), 121 times for 50 patients. In total Ivan E Laboy-Ortiz billed 131 services in 5 codes, and Medicare paid $7,426.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-12-04.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 121 | 50 | $58.01 | $7,019 |
By year: 2022 $9,915 for 161 services; 2023 $8,411 for 136 services; 2024 $7,426 for 131 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ivan E Laboy-Ortiz prescribed most often to Medicare patients was Synthroid (Levothyroxine Sodium), with 3,930 prescriptions and refills. In total Ivan E Laboy-Ortiz wrote 22,298 Medicare prescriptions that cost $3.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Synthroid Levothyroxine Sodium | 3,930 | 5,402 | 536 | $225K |
| Rosuvastatin Calcium Generic | 1,454 | 2,202 | 295 | $14K |
| Atorvastatin Calcium Generic | 1,389 | 2,130 | 294 | $12K |
| Losartan Potassium Generic | 893 | 1,359 | 189 | $7,265 |
| Metformin Hcl Er Metformin Hcl | 727 | 1,169 | 147 | $7,203 |
| Omega-3 Acid Ethyl Esters Generic | 718 | 957 | 137 | $49K |
| Metformin Hcl Generic | 646 | 959 | 126 | $3,867 |
| Levothyroxine Sodium Generic | 633 | 921 | 88 | $6,066 |
| Lantus Insulin Glargine,hum.Rec.Anlog | 621 | 747 | 99 | $58K |
| Simvastatin Generic | 610 | 976 | 127 | $3,634 |
| Trulicity Dulaglutide | 585 | 596 | 81 | $587K |
| Amlodipine Besylate Generic | 553 | 777 | 106 | $2,905 |
| Ezetimibe Generic | 466 | 678 | 100 | $6,393 |
| Jardiance Empagliflozin | 438 | 526 | 83 | $323K |
| Alendronate Sodium Generic | 410 | 581 | 83 | $3,166 |
Brand drugs: 8,597 claims; generic drugs: 13,310 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ivan E Laboy-Ortiz $658 ($658 in general payments such as food, travel and fees) from 7 companies. The largest payer was Boehringer Ingelheim Pharmaceuticals, Inc. with $225.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.